Velsera's Global Data Network Redefines How Pharma and Biotech Access Real-World, Longitudinal Clinicogenomic Data at Scale
Wednesday, July 2, 2025
The federated network is powering faster, smarter drug development across 175+ million patients worldwide
BOSTON, June 24, 2025 /PRNewswire/ -- Velsera, a leading global healthcare technology company offering a universal software platform to connect clinical care with discovery, today announced expanded capabilities and growing impact of its Global Data Network (GDN) - a federated, secure data ecosystem that is transforming how life sciences organizations access and activate real-world, longitudinal clinicogenomic data at scale.
Spanning more than 175 million patient records across 50+ global data providers, the GDN bridges previously siloed data sources - including EMR, genomics, proteomics, transcriptomics, pathology, and radiology - to power faster, more efficient drug discovery and development.
"Traditional data acquisition can take years - time the industry simply doesn't have," said Jamie Littlejohns, Chief Executive Officer at Velsera. "Healthcare produces more data than any other industry, and its impact on humanity is unmatched. Yet, an astonishing 97% of healthcare data goes unused, and over 70% of pharma research data searches end in failure. There's a clear need for a better way to seamlessly connect data with researchers. The GDN enables pharma and biotech teams to move from data request to actionable insights in a matter of weeks - not years - while ensuring security, compliance, and scientific rigor."
A Federated Approach to Unlocking Global, Multi-Modal Data
Unlike centralized models, Velsera's proprietary federated technology enables compliant access to sensitive datasets while keeping data within the control of its source institutions. The result is secure, on-demand access to diverse, high-quality datasets without compromising patient privacy or violating regulatory frameworks like GDPR and HIPAA.
Approximately 40% of the data originates outside the U.S., with growing representation from Europe, Asia, and Latin America, offering global relevance across all major therapeutic areas, with an emphasis on oncology, immunology, neurology, and cardiometabolic diseases.
Fit-for-Purpose Data for Critical R&D Applications
The GDN is purpose-built to solve pharma's most pressing R&D challenges, including:
-- Target and biomarker discovery
-- Patient stratification and clinical trial optimization
-- Label and indication expansion
-- Predictive model development and AI/ML training
-- Companion diagnostic and assay development
With 60% of engagements leveraging clinical and omics data, the GDN supports a wide range of high-impact use cases across research and development. These include real-world patient cohorts built from whole exome sequencing (WES), whole genome sequencing (WGS), RNA-Seq, and increasingly, proteomics - paired with curated longitudinal clinical records.
Accelerating Results Without Compromising Compliance
Velsera's team of data scientists and domain experts works alongside clients to define, source, and harmonize the right datasets. This customer-centric model has led to 80% of data requests being fulfilled within weeks, drastically accelerating time-to-insight for biopharma partners.
To reduce barriers and enable rapid hypothesis validation, Velsera offers flexible engagement models, from multi-year collaborations to short-term access. This allows pharma and biotech teams of all sizes to explore high-value use cases and pilot initiatives with agility.
"We're not just offering data, we're offering the infrastructure and expertise to make that data actionable," said Jamie. "And that's what today's R&D teams need most."
About Velsera:
Velsera's mission is to be the discovery, evidence generation, and clinical delivery platform for precision medicine. We help experts in clinical diagnostics and life sciences make better decisions about providing the right therapy to the right patients at the right time. Velsera was founded in 2023 as a result of the merger of Seven Bridges, PierianDx and UgenTec and operates in the US, Europe and Asia.
Media Contact:
Brian Lassiter
Senior Manager, Growth Marketing
Velsera
397128@email4pr.com
(857) 357-3060 | ext 3060
View original content to download multimedia:https://www.prnewswire.com/news-releases/velseras-global-data-network-redefines-how-pharma-and-biotech-access-real-world-longitudinal-clinicogenomic-data-at-scale-302489658.html
SOURCE Velsera
|
|
|
|
|
 |
Weekly Recap: 11 Tech Press Releases You Need to See | Jan 22, 2026
|
|
Sup AI Sets New Benchmark Record with 52.15% on Humanity's Last Exam | Jan 22, 2026
|
|
DEADLINE ANNOUNCED FOR 2026 NEW TOP-LEVEL DOMAIN APPLICATIONS | Jan 22, 2026
|
|
Trigent Partners with WeWork India to Expand its GCC Footprint | Jan 22, 2026
|
|
Skunk Works® and XTEND Expand Joint All Domain Command and Control for Advanced Mission Execution | Jan 22, 2026
|
|
Exia Labs Brings Keystone to the U.S. Navy via DIU's Blue Object Management Challenge | Jan 22, 2026
|
|
Altair HyperWorks 2026 Delivers Design and Simulation at Scale with AI | Jan 22, 2026
|
|
Glasswall Brings Defense-Level File Sanitization to Every Government Agency and Business Using Microsoft 365 | Jan 22, 2026
|
|
The Roadmap to Securing Your Own Digital Domain is Now Available | Jan 22, 2026
|
|
Buyers Edge Platform Appoints Jaime Selga to Lead Expansion Across the Middle East, Africa & Asia | Jan 22, 2026
|
|
|
